Volume 22, Number 3—March 2016
Dispatch
Signs or Symptoms of Acute HIV Infection in a Cohort Undergoing Community-Based Screening
Martin Hoenigl
, Nella Green, Martha Camacho, Sara Gianella, Sanjay R. Mehta, Davey M. Smith, and Susan J. Little
, Nella Green, Martha Camacho, Sara Gianella, Sanjay R. Mehta, Davey M. Smith, and Susan J. Little
Table 1
Comparison of AHI stage, characteristics of signs or symptoms, CD4+ cell count, and viral load between persons with signs or symptoms before and at the time of NAT versus persons without, San Diego, California, USA, 2007–2014*
| Characteristic |
Total no. persons |
Symptoms before NAT† |
Asymptomatic before NAT |
p value |
Ongoing symptoms at NAT |
Absence of symptoms at NAT |
p value |
|---|---|---|---|---|---|---|---|
| No. persons | 90 | 72 | 18 | 47 | 43 | ||
| Overall no. signs/symptoms in those symptomatic, median (IQR) | 5 (3–7); n = 84 | 5 (4–7) | 5 (2–6); n = 12 | NS | 6 (4–8) | 5 (3–6); n = 37 | NS |
| Duration of symptoms, d, median (IQR) | 9 (5–13); n = 79 | 10 (6–13); n = 67 | 4 (3–7); n = 12 | <0.01 | 11 (8–14); n = 43 | 6 (3–9); n = 36 | <0.01 |
| CD4+ cell count, cells/μL, median (IQR) | 435 (298–597) | 435 (302–586) | 448 (257–615) | NS | 424 (299–592) | 445 (295–610) | NS |
| Viral load, log10 RNA, median (IQR) | 5.4 (4.5–6.3) | 5.8 (4.8–6.4) | 4.5 (3.2–5.0) | <0.01 | 5.6 (4.8–6.4) | 5.0 (3.8–6.1) | 0.07 |
*AHI, acute HIV infection; IQR, interquartile range; NAT, nucleic acid amplification testing; NS, not significant.
†Most frequently observed signs or symptoms that occurred during the 14 days before NAT or were ongoing at the time of NAT were fatigue (53 persons, 59% of the study population), fever (51, 57%), myalgia (48, 53%), headache (41, 46%), night sweats (35, 39%), pharyngitis (32, 36%), and gastrointestinal symptoms (29, 32%).
Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.